Navigation Links
Genetic testing for new warfarin patients is rare, but often inappropriate
Date:4/18/2012

SAN FRANCISCO, April 18, 2012 /PRNewswire/ -- Genetic testing to determine a more accurate initial dosing of warfarin, a drug used to prevent blood clots, remains rare, but is often done for inappropriate patients, according to a new study by Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM). The study will be presented on Friday, April 20, at the Academy of Managed Care Pharmacy (AMCP)'s 24th Annual Meeting & Expo in San Francisco.

The study found that genetic testing associated with warfarin is being performed at a rate of only 4 per 100 individuals, consistent with 2012 American College of Chest Physician guidelines which recommended against routine testing. Despite its rare use, nearly two-thirds of those patients on warfarin who received a genetic test were tested inappropriately, typically those who have already been on the drug for five days or more.

"Based on the increased prevalence of genetic testing, it is clear health plans need to ensure the right member is tested at the right time for the best outcomes," said Patrick Gleason, PharmD, director of clinical outcomes assessment at Prime. "Genetic testing for patients taking warfarin remains controversial and this study shows that while testing is rare, a large number of those being tested are not tested appropriately."

To identify warfarin genetic testing prevalence, appropriateness and cost, researchers from Prime in collaboration with Blue Cross and Blue Shield of Minnesota (BCBSM), reviewed integrated pharmacy and medical claims data from a 1.2 million member commercially insured population. This study emphasizes the value of health plan and PBM collaboration since combining medical and pharmacy data allows for comprehensive assessment of drug safety, effectiveness and total cost of care that ensures clinical pharmacy decisions reflect a complete view of utilization and costs.

There were 8,396 unique members with a warfarin claim during the study period. A genetic testing claim was found in 334 (4 percent) warfarin users and the total paid for genetic testing was $100,312 with a median cost of $152 per member. Researchers used Center for Medicaid and Medicare Services (CMS) criteria to define the appropriateness of testing and categorized the data into those whose tests were performed within five days of the warfarin index claim as appropriate, and greater than five days as inappropriate.

In 2009, CMS decided against covering genetic tests for warfarin use because there was not enough evidence that the tests improved patient health. CMS only reimburses for tests given as part of a clinical trial. Federally-funded clinical trials of genetic tests for warfarin users are currently under way.

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to nearly 20 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minn., Prime Therapeutics is collectively owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Genetics Determine Optimal Drug Dose of Common Anticoagulant
4. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
6. Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products
7. 454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
11. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... BOCA RATON, Fla. , Jan. 19, 2017 ... ), a medical device company specializing in the ... conditions, such as keloids, with superficial radiation therapy, ... quarter and full year 2016 financial results on Thursday, ... The Company will hold a conference call ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange , ... to announce that the first five replication studies ... have been published in eLife today. Despite intense ... the first practical evaluation of reproducibility rates that ... studies. Unlike other assessments of reproducibility, the results ...
(Date:1/19/2017)... PALM BEACH, Florida , January 19, 2017 ... the incoming Trump administration appears serious about reducing ... boost advancements and innovation in the medical drug ... companies forge ahead with new clinical trials and ... and Pharma companies forging ahead with recent developments ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years of ... the clinical trial has been life-saving as she has been on the trial ... Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a ...
(Date:1/20/2017)... ... 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on ... of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of ... 19 years of age, he joined the Navy and got married right out of boot ...
(Date:1/20/2017)... ... 2017 , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection ... is the creation of published author, Gene Gaapf, a retired truck driver, and a ... have been writing since high school and have many different titles,” Gaapf mentions about ...
(Date:1/19/2017)... ... , ... Next week after January 20th, the fear for many is that ... health needs of over 30 million. Many interviews with Dr. Carol Francis at the ... servants were suppose to prioritize. Interviews provided below. , Among those present ...
(Date:1/19/2017)... , ... January 19, 2017 , ... WhoHaha , ... up with the American Heart Association (AHA) to produce a three-part video series that ... will debut as part of the launch of AHA’s Healthy For Good™ movement, which ...
Breaking Medicine News(10 mins):